Get the Stockscreener App
491.75
0.90%
4.505
United Therapeutics Corp stock is traded at $491.75, with a volume of 244.87K.
It is up +0.90% in the last 24 hours and up +3.69% over the past month.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
See More
Previous Close:
$487.25
Open:
$490.07
24h Volume:
244.87K
Relative Volume:
0.48
Market Cap:
$21.17B
Revenue:
$3.08B
Net Income/Loss:
$1.24B
P/E Ratio:
19.20
EPS:
25.6108
Net Cash Flow:
$1.07B
1W Performance:
-3.06%
1M Performance:
+3.69%
6M Performance:
+66.53%
1Y Performance:
+36.48%
1-Day Range:
$480.02
$496.78
1-Week Range:
$480.02
$509.85
52-Week Range:
$266.98
$519.99
United Therapeutics Corp Stock (UTHR) Company Profile
Name
United Therapeutics Corp
Sector
Phone
(301) 608-9292
Address
1000 SPRING ST, SILVER SPRING, MD
Compare UTHR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
491.64 | 20.98B | 3.08B | 1.24B | 1.07B | 25.61 |
|
ZTS
Zoetis Inc
|
125.28 | 55.45B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.61 | 49.25B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.00 | 45.02B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.68 | 35.81B | 16.88B | 666.71M | 251.19M | 0.6132 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-20-25 | Initiated | Wells Fargo | Underweight |
| Sep-26-25 | Initiated | RBC Capital Mkts | Outperform |
| Jun-02-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-25-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-21-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Jul-11-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-12-24 | Upgrade | Goldman | Sell → Neutral |
| Feb-05-24 | Initiated | Leerink Partners | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Dec-06-22 | Initiated | UBS | Buy |
| Dec-05-22 | Initiated | Goldman | Sell |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Sep-20-22 | Reiterated | BofA Securities | Underperform |
| Sep-19-22 | Resumed | Wedbush | Outperform |
| Feb-11-22 | Initiated | BTIG Research | Neutral |
| Jul-14-21 | Upgrade | Argus | Hold → Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Feb-01-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Jun-25-20 | Reiterated | H.C. Wainwright | Neutral |
| Mar-10-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-27-20 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-31-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-03-19 | Initiated | BofA/Merrill | Underperform |
| Aug-01-19 | Upgrade | Jefferies | Underperform → Hold |
| Aug-01-19 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jul-01-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| May-17-19 | Upgrade | UBS | Sell → Neutral |
| May-09-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-12-18 | Upgrade | Standpoint Research | Hold → Buy |
| Aug-08-18 | Downgrade | Credit Suisse | Neutral → Underperform |
| Apr-03-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Feb-22-18 | Reiterated | Barclays | Underweight |
| Jan-18-18 | Resumed | Credit Suisse | Underperform |
| Dec-27-17 | Reiterated | Wedbush | Outperform |
| Apr-27-17 | Reiterated | Wedbush | Outperform |
| Mar-30-17 | Initiated | UBS | Sell |
| Mar-16-17 | Initiated | Credit Suisse | Underperform |
View All
United Therapeutics Corp Stock (UTHR) Latest News
VIRGINIA RETIREMENT SYSTEMS ET Al Sells 137,900 Shares of United Therapeutics Corporation $UTHR - MarketBeat
Here's Why United Therapeutics (UTHR) is a Strong Growth Stock - Yahoo Finance
United Therapeutics (NASDAQ:UTHR) COO Michael Benkowitz Sells 22,500 Shares - MarketBeat
Insider Selling: United Therapeutics (NASDAQ:UTHR) COO Sells 22,500 Shares of Stock - MarketBeat
United Therapeutics EVP & General Counsel Sells 11,000 Shares - TradingView — Track All Markets
Death Cross: Can United Therapeutics Corporation stock sustain market leadershipTrend Reversal & AI Based Buy/Sell Signal Reports - moha.gov.vn
Pacer Advisors Inc. Decreases Position in United Therapeutics Corporation $UTHR - MarketBeat
S&P 500 Futures Flat In Premarket Trading; United Therapeutics, Intel Lag - 富途牛牛
S&P 500 Futures Flat in Premarket Trading; United Therapeutics, Intel Lag - Barron's
United Therapeutics (NASDAQ:UTHR) Reaches New 1-Year HighHere's What Happened - MarketBeat
United Therapeutics (NASDAQ:UTHR) Nasdaq Index Targeted Biotech - Kalkine Media
Insider Sell: Jan Malcolm Sells Shares of United Therapeutics Co - GuruFocus
Jan Malcolm Sells 50 Shares of United Therapeutics (NASDAQ:UTHR) Stock - MarketBeat
United Therapeutics (NASDAQ:UTHR) Director Louis Sullivan Sells 5,950 Shares - MarketBeat
United Therapeutics Director Malcolm Jan Sells Shares - TradingView — Track All Markets
Voya Investment Management LLC Lowers Stock Holdings in United Therapeutics Corporation $UTHR - MarketBeat
Wedge Capital Management L L P NC Reduces Position in United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics (UTHR): Revisiting Valuation After Xenotransplantation Progress and Strong Financial Performance - simplywall.st
Will United Therapeutics Corporation (UTH) stock see valuation expansionJuly 2025 Earnings & Safe Capital Allocation Plans - Улправда
VIX Spike: Will United Therapeutics Corporation (UTH) stock see valuation expansionQuarterly Investment Review & Growth-Oriented Investment Plans - Улправда
Chmn Rothblatt Files To Sell 2,000 Of United Therapeutics Corp [UTHR] - TradingView — Track All Markets
United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 2,000 Shares - MarketBeat
United Therapeutics Executives Engage in Stock Transactions - TradingView — Track All Markets
Published on: 2025-12-19 23:14:09 - Улправда
United Therapeutics stock hits all-time high at 514.05 USD - Investing.com
How resilient is United Therapeutics Corporation stock in market downturnsJuly 2025 Gainers & Free Community Consensus Stock Picks - Улправда
Why United Therapeutics Corporation stock could see breakout soonJuly 2025 Levels & Daily Chart Pattern Signal Reports - DonanımHaber
Osaic Holdings Inc. Raises Stake in United Therapeutics Corporation $UTHR - MarketBeat
Will United Therapeutics Corporation (UTH) stock beat revenue estimatesJuly 2025 Action & Free High Accuracy Swing Entry Alerts - Улправда
Chmn Rothblatt Files To Sell 4,000 Of United Therapeutics Corp [UTHR] - TradingView — Track All Markets
Will Insider Stock Sales Amid EXPAND Xenotransplantation Progress Change United Therapeutics' (UTHR) Narrative? - simplywall.st
James Edgemond Sells 3,517 Shares of United Therapeutics (NASDAQ:UTHR) Stock - MarketBeat
Martine Rothblatt Sells 4,000 Shares of United Therapeutics (NASDAQ:UTHR) Stock - MarketBeat
United Therapeutics (NASDAQ:UTHR) Director Sells $495,950.00 in Stock - MarketBeat
UNITED THERAPEUTICS Director Sells 1,000 Shares - TradingView — Track All Markets
[Form 4] UNITED THERAPEUTICS Corp Insider Trading Activity - Stock Titan
Dir Patusky Files To Sell 1,000 Of United Therapeutics Corp [UTHR] - TradingView — Track All Markets
Texas Permanent School Fund Corp Increases Holdings in United Therapeutics Corporation $UTHR - MarketBeat
Thrivent Financial for Lutherans Has $53.30 Million Holdings in United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics Corporation (NASDAQ:UTHR) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Paul Mahon Sells 11,000 Shares of United Therapeutics (NASDAQ:UTHR) Stock - MarketBeat
AQR Capital Management LLC Boosts Stake in United Therapeutics Corporation $UTHR - MarketBeat
Chmn Rothblatt Sells 8,000 ($3.9M) Of United Therapeutics Corp [UTHR] - TradingView — Track All Markets
United Therapeutics stock hits all-time high at 492.62 USD - Investing.com
Globeflex Capital L P Grows Holdings in United Therapeutics Corporation $UTHR - MarketBeat
Investment Management Corp of Ontario Has $1.57 Million Stock Position in United Therapeutics Corporation $UTHR - MarketBeat
Axa S.A. Raises Stock Position in United Therapeutics Corporation $UTHR - MarketBeat
Insider Selling: United Therapeutics (NASDAQ:UTHR) Director Sells 187 Shares of Stock - MarketBeat
Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells 4,000 Shares of Stock - MarketBeat
Here's Why United Therapeutics (UTHR) is a Strong Momentum Stock - Yahoo Finance
Insider Sell: Nilda Mesa Sells Shares of United Therapeutics Cor - GuruFocus
United Therapeutics Corp Stock (UTHR) Financials Data
Revenue
Net Income
Cash Flow
EPS
United Therapeutics Corp Stock (UTHR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| BENKOWITZ MICHAEL | PRESIDENT AND COO |
Dec 29 '25 |
Sale |
502.79 |
22,500 |
11,312,710 |
0 |
| MAHON PAUL A | EVP & GENERAL COUNSEL |
Dec 24 '25 |
Option Exercise |
146.03 |
11,000 |
1,606,330 |
47,781 |
| MAHON PAUL A | EVP & GENERAL COUNSEL |
Dec 24 '25 |
Sale |
513.18 |
11,000 |
5,644,954 |
36,781 |
| BENKOWITZ MICHAEL | PRESIDENT AND COO |
Dec 22 '25 |
Option Exercise |
146.03 |
7,875 |
1,149,986 |
7,875 |
| BENKOWITZ MICHAEL | PRESIDENT AND COO |
Dec 22 '25 |
Sale |
514.35 |
22,500 |
11,572,963 |
0 |
0.28%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):